Introduction
============

Ossification of ligamentum flavum (OLF) is a relatively common spinal disorder in Eastern Asian countries, with an estimated prevalence of 63.9% in Chinese ([@b1-mmr-20-02-1683]), 36% in Japanese ([@b2-mmr-20-02-1683]) and 16.9% in Korean ([@b3-mmr-20-02-1683]) populations. OLF is characterized by ectopic bone formation in the spinal ligaments and ligamentous tissue hyperplasia ([@b4-mmr-20-02-1683]) that cause spinal canal narrowing and result in the development of myelopathy and radiculopathy ([@b5-mmr-20-02-1683],[@b6-mmr-20-02-1683]). Surgery is the predominant treatment option for OLF; however, the difficulty of surgery and a relatively high risk of complications have to be taken into consideration ([@b7-mmr-20-02-1683]). Therefore, it is necessary to develop more effective, convenient and safe approaches for the treatment of OLF; an improved understanding of its molecular mechanisms may provide insight.

Although the pathogenesis of OLF remains to be elucidated, abnormal expression of osteogenic differentiation and cell proliferation related genes in LF cells may serve important roles ([@b8-mmr-20-02-1683]). The mRNA levels of osteogenic markers \[alkaline phosphatase (ALP), runt-related transcription factor 2, osterix and osteopontin)\] in addition to signaling pathway genes \[bone morphogenetic proteins (BMPs), Wnt/β-catenin and Notch\] ([@b9-mmr-20-02-1683],[@b10-mmr-20-02-1683]), were identified to be higher in patients with OLF compared with non-OLF subjects. Recombinant BMP2 or BMP14 \[also known as growth/differentiation factor (GDF) 5\] modification induced the osteoblastic differentiation of LF cells and promoted bone nodule formation, finally triggering neurological impairment in rat models ([@b11-mmr-20-02-1683],[@b12-mmr-20-02-1683]), while downregulation of Notch2 ameliorated the processes ([@b10-mmr-20-02-1683]). In addition to accelerating osteoblast differentiation via osterix, highly expressed pro-inflammatory cytokines \[tumor necrosis factor (TNF)-α, interleukin (IL)-1a and IL-6\] appear to stimulate cell proliferation and tissue hypertrophy by upregulating cyclin D1 and c-Myc in OLF ([@b13-mmr-20-02-1683]--[@b15-mmr-20-02-1683]). Therefore, targeted regulation of these genes may be potential strategies for the treatment of OLF.

A potential way to endogenously regulate the expression levels of target mRNAs is through microRNAs (miRNAs/miRs) that bind to the 3′-untranslated regions of target genes and subsequently mediate their degradation or translation inhibition ([@b16-mmr-20-02-1683]). Therefore, researchers are exploring the crucial miRNAs that regulate the expression of osteogenic differentiation related genes in OLF. miR-132-3p and miR-615-3p have been demonstrated to be downregulated during osteogenic differentiation of LF cells ([@b17-mmr-20-02-1683],[@b18-mmr-20-02-1683]). Overexpression of miR-615-3p by its mimics suppressed the osteogenic differentiation of LF cells by reducing the expression of GDF5 ([@b17-mmr-20-02-1683]). miR-199b-5p and miR-487b-3p were reported to inhibit osteogenic differentiation in LF cells by downregulating Notch and Wnt signaling pathway genes, respectively ([@b19-mmr-20-02-1683],[@b20-mmr-20-02-1683]). However, the OLF-related miRNAs have rarely been reported and the inflammation-associated miRNAs in OLF have not been identified.

In addition to miRNAs, long non-coding RNAs (lncRNAs) are considered to be crucial in regulating the expression of genes. lncRNAs can competitively bind to miRNAs through their miRNA response elements and influence the regulation of miRNAs for mRNAs, which is called the competing endogenous RNA (ceRNA) hypothesis ([@b21-mmr-20-02-1683]). Therefore, lncRNAs may also be important targets for the treatment of OLF. However, OLF-related lncRNAs are rarely reported, with the exception of the a previous study by Han *et al* ([@b22-mmr-20-02-1683]).

The aim of the present study was to use the datasets uploaded by Han *et al* ([@b22-mmr-20-02-1683]) to further identify novel miRNAs and crucial lncRNAs for OLF based on the miRNA-mRNA and lncRNA-miRNA-mRNA ceRNA regulatory networks. The findings may provide insight for underlying therapeutic strategies for OLF by changing the expression levels of miRNAs and lncRNAs, which could in turn regulate the target genes.

Materials and methods
=====================

### Data sources

A total of two datasets under accession numbers GSE106253 and GSE106256 ([@b22-mmr-20-02-1683]) were downloaded from the Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo/>) on July 2018. The GSE106253 dataset was analyzed to examine the mRNA and lncRNA expression profiles using the microarray technique (platform: GPL21827, Agilent-079487 Arraystar Human LncRNA microarray V4). Then, GSE106256 dataset was analyzed to detect the miRNA expression profile using high throughput sequencing (platform: GPL18573, Illumina NextSeq 500). These two datasets contained the LF tissues from 4 patients with OLF and 4 healthy volunteers.

### Data preprocessing and differential analysis

The raw TXT data were collected from the GEO database and preprocessed using the Linear Models for Microarray data (LIMMA) method ([@b23-mmr-20-02-1683]) (version 3.34.0; <http://www.bioconductor.org/packages/release/bioc/html/limma.html>) in the Bioconductor R package (version 3.4.1; <http://www.R-project.org/>), including base-2 logarithmic (log2) transformation to normalize the skewed distribution, followed by quantile normalization. For the GSE106253 microarray data, all the probe sequences downloaded from the annotation platform GPL21827 were aligned and compared with the human genome using Clustal W program (version 2; <http://www.clustal.org/>) ([@b24-mmr-20-02-1683]) to obtain the expression levels of lncRNA and mRNAs.

The differentially expressed genes (DEGs), differentially expressed lncRNAs (DELs) and differentially expressed miRNAs (DEMs) between the patients with OLF and the healthy controls were identified using the LIMMA method ([@b23-mmr-20-02-1683]). DEGs, DELs and DEMs were screened based on the statistical threshold of \|logFC (fold change)\| \>1 and false discovery rates (FDR) \<0.05. Two-way hierarchical clustering was performed using pheatmap R package (version: 1.0.8; <http://cran.r-project.org/web/packages/pheatmap>) based on Euclidean distance to render a heatmap of DEGs, DELs and DEMs.

### Protein-protein interaction (PPI) network of DEGs

The DEGs were mapped to the Search Tool for the Retrieval of Interacting Genes (STRING; version 10.0; [http://string db.org/](http://string db.org/)) database ([@b25-mmr-20-02-1683]) to acquire PPI pairs. Then, the PPI network was constructed using these PPI pairs and visualized using Cytoscape software (version 3.6.1; [www.cytoscape.org/](www.cytoscape.org/)) ([@b26-mmr-20-02-1683]). Topological features of each node (protein) in the PPI network, including degree \[the number of edges (interactions) of a node\] and betweenness (BC; the number of shortest paths that run through a node), were used to screen hub candidate markers that serve crucial roles in OLF using the CytoNCA plugin in Cytoscape software (<http://apps.cytoscape.org/apps/cytonca>) ([@b27-mmr-20-02-1683]). The Molecular Complex Detection (MCODE; version:1.4.2, <http://apps.cytoscape.org/apps/mcode>) ([@b28-mmr-20-02-1683]) plugin of the Cytoscape software was applied to extract highly interconnected sub-modules from the overall PPI network.

### DEMs-regulated lncRNAs and genes

The DEMs regulated target genes were predicted using the miRwalk database (version 2.0; <http://www.zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2>) ([@b29-mmr-20-02-1683]). The DEMs regulated lncRNAs were predicted using the starBase database (version 2.0; <http://starbase.sysu.edu.cn/index.php>) ([@b30-mmr-20-02-1683]). The target genes and lncRNAs of DEMs were respectively overlapped with the DEGs and DELs to obtain the DEM-DEG and DEM-DEL interaction networks, which were visualized using Cytoscape software ([@b26-mmr-20-02-1683]). Based on the common miRNAs, the DEM-DEG and DEM-DEL networks were integrated to form a DEL-DEM-DEG ceRNA network, which was also visualized using Cytoscape software ([@b26-mmr-20-02-1683]).

### Function enrichment analysis

Gene Ontology (GO; release 2018-10-01; <http://www.geneontology.org>) term and The Kyoto Encyclopedia of Genes and Genomes (KEGG; release 88.0; <http://www.kegg.jp>) pathway enrichment analyses were conducted for genes in each sub-module network and all regulatory networks using the Biological Networks Gene Ontology (BINGO; version 3.0.3; <http://www.psb.ugent.be/cbd/papers/BiNGO/Home.html>) and the Database for Annotation, Visualization and Integrated Discovery (DAVID; version 6.8; <http://david.abcc.ncifcrf.gov>) ([@b31-mmr-20-02-1683]) tools. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Expression pattern of mRNA, lncRNAs and miRNAs in OLF

Based on the cut-off criteria (FDR \<0.05 and \|logFC\| \>1), a total of 828 DEGs (434 upregulated and 394 downregulated) and 119 DELs (94 upregulated and 25 downregulated) were identified in the gene chip GSE106253 ([Fig. 1A](#f1-mmr-20-02-1683){ref-type="fig"}); 81 DEMs, with 25 upregulated and 56 downregulated, were identified in the gene chip GSE106256 ([Fig. 1A](#f1-mmr-20-02-1683){ref-type="fig"}). The top 20 dys-regulated DEGs, DELs and DEMs are summarized in [Table I](#tI-mmr-20-02-1683){ref-type="table"}. The hierarchically clustered heat map indicated that the DEGs and DELs in GSE106253 ([Fig. 1B](#f1-mmr-20-02-1683){ref-type="fig"}), and DEMs in GSE106256 ([Fig. 1B](#f1-mmr-20-02-1683){ref-type="fig"}) were well categorized into OLF and control groups.

### DEGs interaction network construction

By searching the STRING database, 859 interaction pairs between DEGs were collected, which were used to create a PPI network, consisting of 372 nodes (168 upregulated and 204 downregulated; data not shown). A total of 14 nodes were identified and the top 30 genes were ranked following the calculation of the two topological features (the degree and BC), suggesting that 14 genes \[vascular endothelial growth factor (VEGF) A, BMP4, catenin β (CTNNB) 1, G protein subunit gamma (GNG) 4, AKT serine/threonine kinase 1 (AKT1); POTE ankyrin domain family member (POTE) J, SH3 domain containing GRB2 like (SH3GL) 1, endophilin A2, IL10, intercellular adhesion molecule (ICAM) 1, MYC proto-oncogene (MYC), bHLH transcription factor, adenylate cyclase (ADCY) 5, suppressor of cytokine signaling (SOCS) 3, C-C motif chemokine ligand (CCL) 5 and integrin subunit α (ITGA) 4\] may be hub genes in the PPI network ([Table II](#tII-mmr-20-02-1683){ref-type="table"}). In addition, several collagen genes, including collagen type II α 1 chain (COL2A1) and collagen type XIII α 1 chain (COL13A1) may be also important for OLF, according to the degree ranking. A total of seven highly interconnected sub-modules were extracted from the PPI network using the MCODE algorithm ([Fig. 2](#f2-mmr-20-02-1683){ref-type="fig"}). Among them, eight of the hub genes were included in module 1 (COL2A1 and COL13A1; [Fig. 2A](#f2-mmr-20-02-1683){ref-type="fig"}), module 3 (SOCS3; [Fig. 2C](#f2-mmr-20-02-1683){ref-type="fig"}), module 6 (IL10, AKT1, ICAM1 and VEGFA; [Fig. 2F](#f2-mmr-20-02-1683){ref-type="fig"}) and module 7 (GNG4; [Fig. 2G](#f2-mmr-20-02-1683){ref-type="fig"}), suggesting that these eight genes may be particularly crucial for OLF.

Subsequently, BINGO was used to predict the function of these genes in the sub-modules. The results demonstrated that COL2A1 and COL13A1 in module 1 were involved in 'anatomical structure development', 'skeletal system development' and 'cell adhesion'; SOCS3 in module 3 was involved in 'negative regulation of insulin receptor signaling pathway', 'JAK-STAT cascade' and 'regeneration'; IL10, AKT1, ICAM1 and VEGFA in module 6 were involved in 'negative regulation of apoptosis' or 'regulation of immune system process'; and GNG4 in module 7 participated in 'signaling pathway' ([Table III](#tIII-mmr-20-02-1683){ref-type="table"}).

### miRNA-mRNA regulatory network construction

A total of 876 negative miRNA-mRNA regulatory pairs (including miR-210-3p-IL10, hsa-miR-196a-5p-SOCS3, hsa-miR-379-5p-GNG4, has-miR-181b-5p-ADCY5, hsa-miR-329-3p-COL13A1, hsa-miR-222-5p-COL2A1 and hsa-miR-299-3p-WNT7B) were screened from the miRwalk database, which were used to construct a DEM-DEG network ([Fig. 3](#f3-mmr-20-02-1683){ref-type="fig"}). This constructed DEM-DEG regulatory network included 344 nodes, comprising of 73 DEMs (23 upregulated; 50 downregulated) and 271 DEGs (122 upregulated; 149 downregulated). GO biological process terms and KEGG pathways were analyzed to predict the potential functions of the DEGs in this DEM-DEG regulatory network using the DAVID database. The results demonstrated that these DEGs were enriched in 28 GO biological processes, including 'GO:0042127\~regulation of cell proliferation' (IL10 and VEGFA), 'GO:0002250\~adaptive immune response' (IL10 and VEGFA), 'GO:0001501\~skeletal system development' (COL2A1 and COL13A1), 'GO:0001503\~ossification' (COL2A1 and COL13A1), 'GO:0060348\~bone development' (COL2A1 and COL13A1), 'GO:0009725\~response to hormone stimulus' (GNG4 and ADCY5), 'GO:0001666\~response to hypoxia' (SOCS3) and 'GO:0042981\~regulation of apoptosis' (SOCS3; [Table IV](#tIV-mmr-20-02-1683){ref-type="table"}; [Fig. 4](#f4-mmr-20-02-1683){ref-type="fig"}). In addition, these DEGs were enriched in eight KEGG pathways, including 'Hsa04510: Focal adhesion' (COL2A1 and VEGFA), 'Hsa00230: Purine metabolism' (ADCY5), 'Hsa04150: mTOR signaling pathway' (VEGFA), 'Hsa04310: Wnt signaling pathway' (WNT7B), 'Hsa04920: Adipocytokine signaling pathway' (SOCS3) and 'Hsa04660: T cell receptor signaling pathway' (IL10; [Table IV](#tIV-mmr-20-02-1683){ref-type="table"}; [Fig. 4](#f4-mmr-20-02-1683){ref-type="fig"}).

### lncRNA-miRNA-mRNA ceRNA regulatory network construction

A total of 33 miRNA-lncRNA regulatory pairs \[including small nucleolar RNA host gene (SNHG) 16-hsa-miR-196a-5p, ankyrin repeat and SOCS box containing 16 (ASB16)-AS1-hsa-miR-379-5p, nuclear enriched abundant transcript (NEAT) 1-has-miR-181b-5p and rhophilin (RHPN) 1-AS1-hsa-miR-299-3p\] were screened from the starBase database, which were used to construct a DEM-DEL regulatory network ([Fig. 5](#f5-mmr-20-02-1683){ref-type="fig"}). This established DEM-DEL regulatory network included 31 nodes, comprising of 22 DEMs (9 upregulated; 13 downregulated) and nine DELs (6 upregulated; 3 downregulated).

Following the integration of the DEM-DEG and DEM-DEL regulatory networks, an lncRNA-miRNA-mRNA ceRNA network (including SNHG16-hsa-miR-196a-5p-SOCS3, ASB16-AS1-hsa-miR-379-5p-GNG4, NEAT1-has-miR- 181b-5p-ADCY5 and RHPN1-AS1-hsa-miR-299-3p-WNT7B) was constructed ([Fig. 6](#f6-mmr-20-02-1683){ref-type="fig"}), in which 165 nodes (8 DELs; 21 DEMs; 136 DEGs) and 245 edges (32 DEL-DEM and 213 DEM-DEG interaction pairs) were involved. The functional analysis of the genes in this ceRNA network also demonstrated that 'GO:0009725\~response to hormone stimulus' (GNG4 and ADCY5), 'GO:0001666\~response to hypoxia' (SOCS3), 'Hsa00230: Purine metabolism' (ADCY5), 'Hsa04920: Adipocytokine signaling pathway' (SOCS3), 'Hsa04062: Chemokine signaling pathway' (GNG4 and ADCY5) and 'Hsa04310: Wnt signaling pathway' (WNT7B) were enriched ([Table V](#tV-mmr-20-02-1683){ref-type="table"}; [Fig. 7](#f7-mmr-20-02-1683){ref-type="fig"}).

Discussion
==========

Although the same datasets were used from the study by Han *et al* ([@b22-mmr-20-02-1683]), the present study applied several different bioinformatics methods aiming to screen crucial molecular mechanisms for OLF: i) Hub genes were identified by constructing the PPI network, ranking the nodes according to the topological properties and extracting the sub-modules; ii) the target genes of miRNAs were predicted using the miRwalk database, which contained 12 prediction algorithms, not only three; and iii) the key lncRNAs were identified on the basis of the lncRNA-miRNA-mRNA ceRNA regulatory network, not the lncRNA-mRNA co-expression network. Accordingly, the present study may provide certain novel miRNAs and lncRNAs for explaining the pathogenesis of OLF, and developing novel therapeutic approaches for OLF. As a result, it was identified, for the first time to the best of the authors\' knowledge, that miR-210-3p may be a key miRNA for OLF by regulating immune-related gene IL10. lncRNA SNHG16, ASB16-AS1 and NEAT1 may also be important by acting as ceRNAs for miR-196a-5p, miR-379-5p and miR-181b-5p to modulate the expression levels of miRNA target genes SOCS3, GNG4 and ADCY5, respectively. SOCS3 was involved in 'response to hypoxia', 'regulation of apoptosis' and 'regeneration', while GNG4 and ADCY5 participated in the 'Chemokine signaling pathway'. All these mRNAs were hub genes in the PPI network.

Previous studies have demonstrated that inflammatory cytokines promote hypertrophy and ossification of LF cells, but only a number of them (TNF-α, IL-1α and IL-6) have been investigated ([@b13-mmr-20-02-1683]--[@b15-mmr-20-02-1683]). The present study predicted that IL10, SOCS3 and ADCY5 may be anti-inflammatory due to their downregulation, while GNG4 may be pro-inflammatory due to its upregulation in OLF. The associations of the identified genes with inflammation can be indirectly confirmed. For example, IL10 is a known anti-inflammatory cytokine that was identified to have lower expression in subligamentous type of disc degeneration ([@b8-mmr-20-02-1683]). SOCS3 may mediate the blockade of inflammation by inhibiting Janus kinase-STAT3 activity and to prevent the abnormal expression of IL-6 ([@b32-mmr-20-02-1683],[@b33-mmr-20-02-1683]). ADCY5 was also demonstrated to be significantly downregulated in cytokine-related hepatocellular carcinoma ([@b34-mmr-20-02-1683]) and prostate cancer ([@b35-mmr-20-02-1683]). Although GNG4 was previously demonstrated to be downregulated in glioblastoma cells and exogenous overexpression of GNG4 can inhibit stromal cell-derived factor 1/C-X-C motif chemokine receptor 4-dependent chemokine signaling ([@b36-mmr-20-02-1683]), two recent studies observed that GNG4 was significantly upregulated in patients with colon cancer ([@b37-mmr-20-02-1683]) and cardiovascular events ([@b38-mmr-20-02-1683]), indicating its potential pro-inflammatory and pro-proliferation roles. In agreement with these two studies, the present study additionally identified that GNG4 was upregulated in LF cells.

Although there have been previous studies that examined the roles of miRNAs in OLF, all of these studies focused on miRNAs that regulate osteogenic differentiation related genes ([@b17-mmr-20-02-1683]--[@b20-mmr-20-02-1683],[@b39-mmr-20-02-1683]). miRNAs related with inflammation and cell proliferation in OLF have rarely been reported. Using comprehensive analysis, the present study identified that miR-210-3p, miR-196a-5p and miR-181b-5p targeting anti-inflammatory IL10, SOCS3 and ADCY5, respectively, were upregulated, but miR-379-5p, which targets pro-inflammatory GNG4, was downregulated in OLF. The interaction associations between miR-210 and miR-196 and their target genes has been demonstrated in other inflammatory diseases. For example, administration of agomir-210 significantly upregulated IL-10 and attenuated cellular apoptosis and inflammation in an injured rat spinal cord, ultimately improving functional recovery ([@b40-mmr-20-02-1683]). Ectopic expression of miR-196 promoted stemness and chemoresistance of colorectal cancer cells by targeting SOCS3, a negative regulator of the STAT3 signaling pathway ([@b41-mmr-20-02-1683]). miR-181b has been reported to stimulate inflammation via the nuclear factor-κB signaling pathway ([@b42-mmr-20-02-1683]), while miR-379 significantly suppresses the invasive capacity of cancer cells by inhibiting cytokine IL-18 ([@b43-mmr-20-02-1683]). These findings may indirectly verify the important roles of these miRNAs in inflammatory OLF.

Furthermore, the present study also identified several crucial lncRNAs that regulated the mentioned inflammation and cell proliferation related genes based on the ceRNA hypothesis, including downregulated lncRNA SNHG16/NEAT1 and upregulated ASB16-AS1. Although their mechanisms in OLF require confirmation in further experiments, previous studies have indirectly identified their underlying associations. Zhao *et al* ([@b44-mmr-20-02-1683]) demonstrated that NEAT1 was decreased in primary acute myeloid leukemia cells and THP-1 monocytes compared with normal cells; overexpression of NEAT1 inhibits cell proliferation, promotes apoptosis and affects the cell cycle. Overexpressed ASB16-AS1 has been reported to increase the expression of osteoblastogenesis-related genes (BMP2 and ALP) ([@b45-mmr-20-02-1683]) which were previously demonstrated to be induced by inflammatory cytokines ([@b14-mmr-20-02-1683]). The roles of SNHG16 on cell proliferation may be controversial, although the majority of studies have demonstrated that SNHG16 may functions as an oncogene ([@b46-mmr-20-02-1683],[@b47-mmr-20-02-1683]). However, the present study identified that expression of SNHG16 decreased in LF cells of patients with OLF compared with the controls and further investigation is necessary to elucidate the underlying biological associations between SNHG16 and OLF.

In addition to inflammation genes, the present study also identified the significant miRNAs and lncRNAs associated with osteogenic differentiation related genes. miR-329-3p and miR-222-5p were involved in ossification by regulating COL13A1 and COL2A1, respectively. RHPN1-AS1 functioned as a ceRNA for miR-299-3p to influence the Wnt signaling pathway through WNT7B. These results were in agreement with a previous study, in which inhibition of miR-222-3p in human bone mesenchymal stem cells promoted the expression of osteoblast-specific genes, ALP activity, and matrix mineralization, while overexpression of miR-222-3p inhibited osteoblast differentiation ([@b48-mmr-20-02-1683]). The roles of other miRNAs and lncRNAs require further investigation.

There are certain limitations to the present study. Only two datasets were included to examine the molecular mechanisms of OLF due to limited previous studies. Also, the current sample size of these datasets was small. Therefore, further studies using high-throughput sequencing experiments with larger clinical samples would be valuable. Another limitation is that this is a preliminary study to identify the crucial miRNAs and lncRNAs for OLF. Further *in vitro* and *in vivo* experiments are necessary to confirm the expression levels of these identified miRNAs and lncRNAs in OLF, and to demonstrate the regulatory associations between them and the downstream DEGs.

In conclusion, the present study identified several inflammation and osteogenic differentiation related miRNA-mRNAs (miR-210-3p-IL10, hsa-miR-329-3p-COL13A1 and hsa-miR-222-5p-COL2A1) or lncRNA-miRNA-mRNA interaction axes (SNHG16-hsa-miR-196a-5p-SOCS3, ASB16-AS1-hsa-miR-379-5p-GNG4, NEAT1-has-miR-181b- 5p-ADCY5 and RHPN1-AS1-hsa-miR-299-3p-WNT7B), which may be involved in the pathogenesis of OLF. These miRNAs and lncRNAs may be natural, endogenous and nontoxic drug targets for the treatment of OLF.
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![Expression pattern of mRNA, lncRNAs and miRNAs in patients with OLF and healthy individuals. (A) Volcano plot shows the number and distribution of mRNAs and lncRNAs in GSE106253, and miRNAs in GSE106256. Red dots indicated differentially expressed genes; black dots indicated no significant difference in expression. (B) Heat map showing differentially expressed mRNAs and lncRNAs in GSE106253, and miRNAs in GSE106256 when comparing OLF with the control. Red and blue denoted high and low expression, respectively. lncRNA, long non-coding RNA; miRNA, microRNA; OLF, ossification of ligamentum flavum; FC, fold change; FDR, false discovery rate.](MMR-20-02-1683-g00){#f1-mmr-20-02-1683}

![Modules extracted from the protein-protein interaction network. (A) Module 1, (B) module 2, (C) module 3, (D) module 4, (E) module 5, (F) module 6 and (G) module 7 are presented. Red and green denoted upregulated and downregulated expression, respectively. The color depth is in proportion to differential levels. The size of the proteins is in proportion to the number of its interaction pairs.](MMR-20-02-1683-g01){#f2-mmr-20-02-1683}

![miRNA-mRNA interaction network. Red and green denoted upregulated and downregulated expression, respectively. The color depth is in proportion to differential levels. Squares represent miRNAs; circles represent mRNAs. mi, micro; miR, microRNA; FC, fold change.](MMR-20-02-1683-g02){#f3-mmr-20-02-1683}

![Function enrichment for the genes in the microRNA-mRNA interaction network. (A) GO analysis and (B) KEGG pathways. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; ECM, extracellular matrix.](MMR-20-02-1683-g03){#f4-mmr-20-02-1683}

![lncRNA-miRNA interaction network. Diamonds represent lncRNAs and squares represent miRNAs. Red and green denoted upregulated and downregulated expression, respectively. The color depth is in proportion to differential levels. lnc, long non-coding RNA; miRNA/miR, microRNA.](MMR-20-02-1683-g04){#f5-mmr-20-02-1683}

![Competing endogenous RNA interaction network of lncRNA-miRNA-mRNA. Red and green denoted upregulated and downregulated expression, respectively. The color depth is in proportion to differential levels. Squares represent miRNAs; circles represent mRNAs; and diamonds represent lncRNAs. lncRNA, long non-coding RNA; miRNA/miR, microRNA.](MMR-20-02-1683-g05){#f6-mmr-20-02-1683}

![Function enrichment for the genes in the lncRNA-miRNA-mRNA interaction network. (A) GO analysis and (B) KEGG pathways. lncRNA, long non-coding RNA; miRNA, microRNA; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.](MMR-20-02-1683-g06){#f7-mmr-20-02-1683}

###### 

Top 10 upregulated and downregulated differentially expressed genes, lncRNAs and miRNAs.

  A, Upregulated                                                                                                  
  ---------------------- ------------- ----------- ------------ ------------ ----------- ----------- ------------ -----------
  hsa-miR-653-3p         8.30×10^4^    4.00        LINC01549    2.31×10^2^   5.50        PKIB        6.80×10^3^   6.29
  hsa-miR-489-3p         2.33×10^2^    3.81        CLSTN2-AS1   1.45×10^2^   4.678       AMTN        2.95×10^2^   5.47
  hsa-miR-508-3p         4.51×10^2^    3.59        LINC00347    2.04×10^2^   4.09        WISP3       1.77×10^2^   5.34
  hsa-miR-4683           1.95×10^3^    3.46        LINC02203    7.15×10^3^   3.84        ADCYAP1     1.70×10^2^   5.32
  hsa-miR-138-5p         1.70×10^3^    3.22        LINC01508    4.07×10^2^   3.75        COL9A1      1.11×10^2^   5.17
  hsa-miR-653-5p         3.54×10^5^    3.14        WASIR2       1.07×10^2^   3.22        SERPINA11   1.13E-02     5.13
  hsa-miR-4473           1.72×10^2^    2.88        LINC01440    9.83×10^3^   3.18        CLEC3A      1.89×10^2^   5.08
  hsa-miR-483-3p         1.65×10^3^    2.86        LINC02249    1.12×10^2^   3.14        SLITRK6     3.88×10^2^   5.03
  hsa-miR-181b-3p        2.28×10^2^    2.58        DSG1-AS1     2.27×10^2^   3.07        ZMAT4       2.11×10^2^   4.92
                                                                                                                  
  **B, Downregulated**                                                                                            
                                                                                                                  
  **miRNA**              **FDR**       **logFC**   **lncRNA**   **FDR**      **logFC**   **mRNA**    **FDR**      **logFC**
                                                                                                                  
  hsa-miR-495-3p         2.41×10^6^    −3.16       LINC01706    2.24×10^2^   3.06        ITIH6       1.11×10^2^   4.73
  hsa-miR-495-3p         2.41×10^6^    −3.16       LINC00601    3.88×10^2^   −1.839      FAM3B       1.43×10^2^   −3.06
  hsa-miR-377-5p         2.07×10^2^    −3.18       LINC01730    4.24×10^2^   −1.85       ZIC3        1.79×10^2^   −3.22
  hsa-miR-551b-3p        2.04×10^3^    −3.21       FAM230B      2.48×10^2^   −1.88       ANGPTL4     4.87×10^2^   −3.31
  hsa-miR-369-5p         3.61×10^3^    −3.28       FLG-AS1      1.63×10^2^   −1.93       SOCS3       2.20×10^2^   −3.43
  hsa-miR-1185-1-3p      2.11×10^3^    3.76        SNHG16       2.56×10^2^   −2.06       GPT         4.11×10^2^   −3.49
  hsa-miR-539-3p         1.72×10^2^    −3.91       LINC01615    2.14×10^2^   −2.08       ADAMTS4     3.43×10^2^   −3.73
  hsa-miR-222-5p         1.02×10^2^    −4.09       HIPK1-AS1    1.98×10^2^   −2.30       GPD1        4.02×10^2^   −3.79
  hsa-miR-412-5p         1.02×10^2^    −4.09       LINC01485    3.95×10^2^   −2.53       FAM71A      1.67×10^2^   −3.84
  hsa-miR-4443           3.53×10^4^    −4.25       MEG3         2.80×10^2^   −2.53       SAA1        3.77×10^2^   −3.89
  hsa-miR-122-5p         4.40×10^10^   −6.87       VPS9D1-AS1   1.30×10^2^   −2.65       CCL2        4.29×10^2^   −3.99

lncRNA, long non-coding RNA; miRNA/miR, microRNA; FDR, false discovery rate; FC, fold change.

###### 

Top 30 genes ranked by topological characteristics.

  Genes     Degree   Genes      Betweenness centrality   Overlap   LogFC
  --------- -------- ---------- ------------------------ --------- -------
  AKT1      31       TBC1D10B   1.0000                   VEGFA     −1.55
  CTNNB1    30       GPR153     1.0000                   BMP4      2.26
  VEGFA     29       PLK3       1.0000                   CTNNB1    −1.90
  GNG4      26       POLQ       0.8333                   GNG4      3.49
  ADCY5     26       LMNA       0.6667                   AKT1      −1.27
  CCL5      19       SUN2       0.6667                   POTEJ     −1.94
  IL10      19       EXO1       0.5000                   SH3GL1    −1.62
  POTEJ     16       CTNNB1     0.2625                   IL10      −2.29
  SAA1      16       AKT1       0.1816                   ICAM1     1.38
  SOCS3     15       VEGFA      0.1401                   MYC       −1.19
  NMU       15       GNA12      0.1294                   ADCY5     −1.46
  NMUR1     15       ADCY5      0.1213                   SOCS3     −3.43
  ITGA4     15       YWHAZ      0.0964                   CCL5      1.38
  MYC       15       POLR2D     0.0957                   ITGA4     1.64
  COL4A2    14       IL10       0.0833                             
  COL9A2    14       ITGA4      0.0756                             
  SH3GL1    14       POTEJ      0.0725                             
  COL9A3    14       GBF1       0.0718                             
  CCL2      14       MYC        0.0693                             
  ICAM1     14       PLA2G4F    0.0665                             
  COL6A1    13       SMG5       0.0639                             
  COL10A1   13       CTTN       0.0580                             
  BMP4      13       PLD4       0.0550                             
  COL6A2    13       ICAM1      0.0545                             
  COL9A1    13       SOCS3      0.0539                             
  CD40LG    13       RPS18      0.0536                             
  COL2A1    13       CCL5       0.0532                             
  CRTAP     12       RBBP4      0.0510                             
  KBTBD7    12       GNG4       0.0492                             
  COL22A1   12       FZD9       0.0475                             
  PPIB      12       BMP4       0.0457                             
  NT5E      12       SH3GL1     0.0448                             
  COL13A1   12       FOXO3      0.0426                             
  PIK3R3    12       TBL2       0.0424                             

FC, fold change.

###### 

Function enrichment for genes in the different modules.

  A, M1                                                                                             
  ----------- ------------- ----------------------------------------------------------------------- ---------------------------------------------------------------------------------------------
  48731       4.98×10^3^    System development                                                      COL2A1, COL13A1, COL9A1, COL10A1, COL9A3, COL9A2
  48856       7.99×10^3^    Anatomical structure development                                        COL2A1, COL13A1, COL9A1, COL10A1, COL9A3, COL9A2
  1501        2.69×10^6^    Skeletal system development                                             COL2A1, COL13A1, COL9A1, COL10A1, COL9A2
  7155        1.08×10^4^    Cell adhesion                                                           COL2A1, COL13A1, COL6A2, COL6A1, COL9A1
  22610       1.08×10^4^    Biological adhesion                                                     COL2A1, COL13A1, COL6A2, COL6A1, COL9A1
  30198       5.74×10^5^    Extracellular matrix organization                                       COL2A1, COL4A2, COL6A2
  43062       2.12×10^4^    Extracellular structure organization                                    COL2A1, COL4A2, COL6A2
  16337       1.22×10^3^    Cell-cell adhesion                                                      COL2A1, COL13A1, COL6A2
                                                                                                    
  **B, M2**                                                                                         
                                                                                                    
  **GO-ID**   **P-value**   **Description**                                                         **Genes in test set**
                                                                                                    
  23052       6.96×10^7^    Signaling                                                               GPR27, P2RY14, PTGER2, ADM, GIP, ADCYAP1, GPR176, CALCR, CCL5, NMU, CRH, OXER1, NMUR1, DRD1
  7166        7.13×10^7^    Cell surface receptor linked signaling pathway                          ADCYAP1, GPR176, CALCR, P2RY14, PTGER2, NMU, OXER1, NMUR1, DRD1, GIP
  23033       7.80×10^6^    Signaling pathway                                                       ADCYAP1, GPR176, CALCR, P2RY14, PTGER2, NMU, OXER1, ADM, NMUR1, DRD1, GIP
  23046       8.09×10^5^    Signaling process                                                       GPR27, GPR176, CALCR, CCL5, NMU, CRH, ADM, NMUR1, DRD1, GIP
  23060       8.09×10^5^    Signal transmission                                                     GPR27, GPR176, CALCR, CCL5, NMU, CRH, ADM, NMUR1, DRD1, GIP
  50896       2.69×10^4^    Response to stimulus                                                    CALCR, P2RY14, CCL5, NMU, SAA1, CRH, ADM, DRD1, CXCL3, CXCL2, CCL28, GIP
  65007       1.12×10^2^    Biological regulation                                                   GPR27, PTGER2, ADM, GIP, ADCYAP1, CALCR, CCL5, NMU, SAA1, CRH, OXER1, NMUR1, DRD1, CCL28
  50794       1.32×10^2^    Regulation of cellular process                                          GPR27, PTGER2, ADM, GIP, ADCYAP1, CALCR, CCL5, NMU, SAA1, CRH, OXER1, NMUR1, DRD1
                                                                                                    
  **C, M3**                                                                                         
                                                                                                    
  **GO-ID**   **P-value**   **Description**                                                         **Genes in test set**
                                                                                                    
  7017        5.49×10^5^    Microtubule-based process                                               RNF19A, KIF5A, KIF1C, KIF1A
  46627       1.03×10^4^    Negative regulation of insulin receptor signaling pathway               SOCS3, SOCS1
  7018        1.20×10^4^    Microtubule-based movement                                              KIF5A, KIF1C, KIF1A
  46626       1.59×10^4^    Regulation of insulin receptor signaling pathway                        SOCS3, SOCS1
  6890        1.59×10^4^    Retrograde vesicle-mediated transport, Golgi to ER                      GBF1, KIF1C
  32570       2.08×10^4^    Response to progesterone stimulus                                       SOCS3, SOCS1
  7259        4.46×10^4^    JAK-STAT cascade                                                        SOCS3, SOCS1
  31100       4.72×10^4^    Organ regeneration                                                      SOCS3, SOCS1
  32355       1.44×10^3^    Response to estradiol stimulus                                          SOCS3, SOCS1
  16192       1.52×10^3^    Vesicle-mediated transport                                              KDELR1, GBF1, KIF1C, TMED2
  51246       1.99×10^3^    Regulation of protein metabolic process                                 UBE2F, SOCS3, SOCS1, UBE2E2
  31099       2.26×10^3^    Regeneration                                                            SOCS3, SOCS1
  46907       2.36×10^3^    Intracellular transport                                                 KDELR1, GBF1, KIF1C, KIF1A
                                                                                                    
  **D, M4**                                                                                         
                                                                                                    
  **GO-ID**   **P-value**   **Description**                                                         **Genes in test set**
                                                                                                    
  16043       1.03×10^3^    Cellular component organization                                         TFRC, ARPC4, EPS15, SH3GL1
  16044       7.41×10^5^    Cellular membrane organization                                          TFRC, EPS15, SH3GL1
  61024       7.47×10^5^    Membrane organization                                                   TFRC, EPS15, SH3GL1
  16192       2.71×10^4^    Vesicle-mediated transport                                              TFRC, EPS15, SH3GL1
  43623       6.55×10^4^    Cellular protein complex assembly                                       ARPC4, EPS15
  10324       1.41×10^3^    Membrane invagination                                                   TFRC, SH3GL1
  6897        1.41×10^3^    Endocytosis                                                             TFRC, SH3GL1
  34622       2.83×10^3^    Cellular macromolecular complex assembly                                ARPC4, EPS15
  34621       3.58×10^3^    Cellular macromolecular complex subunit organization                    ARPC4, EPS15
  6461        7.17×10^3^    Protein complex assembly                                                ARPC4, EPS15
  70271       7.17×10^3^    Protein complex biogenesis                                              ARPC4, EPS15
  65003       1.26×10^2^    Macromolecular complex assembly                                         ARPC4, EPS15
                                                                                                    
  **E, M5**                                                                                         
                                                                                                    
  **GO-ID**   **P-value**   **Description**                                                         **Genes in test set**
                                                                                                    
  6139        6.85×10^9^    Nucleobase, nucleoside, nucleotide and nucleic acid metabolic process   NT5E, PABPN1, ENTPD4, SRSF1, POLR2D, AMPD1, PPWD1, AKD1, CD2BP2, PRPF40A, CHERP
  34641       3.49×10^8^    Cellular nitrogen compound metabolic process                            NT5E, PABPN1, ENTPD4, SRSF1, POLR2D, AMPD1, PPWD1, AKD1, CD2BP2, PRPF40A, CHERP
  6807        6.30×10^8^    Nitrogen compound metabolic process                                     NT5E, PABPN1, ENTPD4, SRSF1, POLR2D, AMPD1, PPWD1, AKD1, CD2BP2, PRPF40A, CHERP
  44237       3.34×10^4^    Cellular metabolic process                                              NT5E, PABPN1, ENTPD4, SRSF1, POLR2D, AMPD1, PPWD1, AKD1, CD2BP2, PRPF40A, CHERP
  44238       5.98×10^4^    Primary metabolic process                                               NT5E, PABPN1, ENTPD4, SRSF1, POLR2D, AMPD1, PPWD1, AKD1, CD2BP2, PRPF40A, CHERP
  8152        1.95×10^3^    Metabolic process                                                       NT5E, PABPN1, ENTPD4, SRSF1, POLR2D, AMPD1, PPWD1, AKD1, CD2BP2, PRPF40A, CHERP
  90304       9.29×10^6^    Nucleic acid metabolic process                                          NT5E, PABPN1, SRSF1, POLR2D, PPWD1, CD2BP2, PRPF40A, CHERP
  44260       4.95×10^3^    Cellular macromolecule metabolic process                                NT5E, PABPN1, SRSF1, POLR2D, PPWD1, CD2BP2, PRPF40A, CHERP
  43170       1.20×10^2^    Macromolecule metabolic process                                         NT5E, PABPN1, SRSF1, POLR2D, PPWD1, CD2BP2, PRPF40A, CHERP
  6396        2.09×10^7^    RNA processing                                                          PABPN1, SRSF1, POLR2D, PPWD1, CD2BP2, PRPF40A, CHERP
  16070       7.49×10^6^    RNA metabolic process                                                   PABPN1, SRSF1, POLR2D, PPWD1, CD2BP2, PRPF40A, CHERP
  10467       4.36×10^5^    Gene expression                                                         PABPN1, SRSF1, POLR2D, PPWD1, CD2BP2, PRPF40A, CHERP
                                                                                                    
  **F, M6**                                                                                         
                                                                                                    
  **GO-ID**   **P-value**   **Description**                                                         **Genes in test set**
                                                                                                    
  48583       8.51×10^11^   Regulation of response to stimulus                                      IL10, CD40LG, SERPINE1, CCL2, AKT1, VEGFA, ICAM1
  32879       8.51×10^10^   Regulation of localization                                              IL10, CD40LG, SERPINE1, CCL2, AKT1, VEGFA, ICAM1
  48522       1.05×10^6^    Positive regulation of cellular process                                 IL10, CD40LG, SERPINE1, CCL2, AKT1, VEGFA, ICAM1
  48518       2.07×10^6^    Positive regulation of biological process                               IL10, CD40LG, SERPINE1, CCL2, AKT1, VEGFA, ICAM1
  50896       6.78×10^5^    Response to stimulus                                                    IL10, CD40LG, SERPINE1, CCL2, AKT1, VEGFA, ICAM1
  50794       2.94×10^3^    Regulation of cellular process                                          IL10, CD40LG, SERPINE1, CCL2, AKT1, VEGFA, ICAM1
  50789       4.23×10^3^    Regulation of biological process                                        IL10, CD40LG, SERPINE1, CCL2, AKT1, VEGFA, ICAM1
  65007       6.33×10^3^    Biological regulation                                                   IL10, CD40LG, SERPINE1, CCL2, AKT1, VEGFA, ICAM1
  43066       2.17×10^9^    Negative regulation of apoptosis                                        IL10, CD40LG, SERPINE1, CCL2, AKT1, VEGFA
  43069       2.35×10^9^    Negative regulation of programmed cell death                            IL10, CD40LG, SERPINE1, CCL2, AKT1, VEGFA
  60548       2.66×10^9^    Negative regulation of cell death                                       IL10, CD40LG, SERPINE1, CCL2, AKT1, VEGFA
  2682        4.47×10^9^    Regulation of immune system process                                     IL10, CD40LG, SERPINE1, CCL2, VEGFA, ICAM1
  42981       2.92×10^7^    Regulation of apoptosis                                                 IL10, CD40LG, SERPINE1, CCL2, AKT1, VEGFA
  43067       3.08×10^7^    Regulation of programmed cell death                                     IL10, CD40LG, SERPINE1, CCL2, AKT1, VEGFA
  10941       3.24×10^7^    Regulation of cell death                                                IL10, CD40LG, SERPINE1, CCL2, AKT1, VEGFA
  2376        5.51×10^7^    Immune system process                                                   IL10, CD40LG, CCL2, AKT1, VEGFA, ICAM1
                                                                                                    
  **G, M7**                                                                                         
  **GO-ID**   **P-value**   **Description**                                                         **Genes in test set**
                                                                                                    
  23033       9.95×10^6^    Signaling pathway                                                       TRIO, GRP, PTGER1, GNG4, KISS1R, PIK3R3
  7166        3.16×10^5^    Cell surface receptor linked signaling pathway                          TRIO, GRP, PTGER1, KISS1R, PIK3R3
  23052       1.10×10^4^    Signaling                                                               TRIO, GRP, PTGER1, GNG4, KISS1R, PIK3R3
  7186        7.80×10^4^    G-protein coupled receptor protein signaling pathway                    GRP, PTGER1, KISS1R

GO, gene ontology; M, module.

###### 

Function enrichment for genes in microRNA-mRNA network.

  A, Biological process                                                    
  ---------------------------------------------------------- ------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GO:0042127\~regulation of cell proliferation               4.65×10^5^    FGF18, BAP1, EIF5A, GJA1, SESN1, GLI3, IL10, CDH5, MSX2, SERPINE1, SPN, IHH, PTGER2, ESRRA, RBBP4, TNFRSF13C, LIFR, SKI, CDC25B, NCK2, PRKCQ, ATF3, ADM, VEGFA, MYO16, HBEGF, HGS, LAMC1, TGFB1I1, PLAU
  GO:0002250\~adaptive immune response                       2.87×10^4^    EXO1, C8B, CADM1, CD40LG, SLA2, VEGFA, IL10, RAB27A
  GO:0010033\~response to organic substance                  4.04×10^4^    CALCR, IL1R1, DRD1, LEPR, ADCY5, CCL5, IL10, MSX2, COL6A2, SCARB1, PPP3CA, PIK3R3, GNG4, DDAH2, IHH, MB, IRAK1, ACADS, SOCS3, STRN3, LIFR, PPARGC1B, ERP44, PRKCQ, ADM, TFRC
  GO:0001501\~skeletal system development                    9.07×10^4^    FGF18, ESRRA, COL13A1, DMP1, COL2A1, FRZB, GLI3, CHAD, MSX2, COL9A2, TNFSF11, PHEX, CHRD, ADAMTS4, IHH
  GO:0009719\~response to endogenous stimulus                1.23×10^3^    CALCR, DRD1, ACADS, SOCS3, STRN3, LEPR, ADCY5, CCL5, IL10, PPARGC1B, PRKCQ, ADM, PPP3CA, PIK3R3, GNG4, IHH, MB
  GO:0009725\~response to hormone stimulus                   1.24×10^3^    CALCR, DRD1, ACADS, SOCS3, STRN3, LEPR, ADCY5, CCL5, IL10, PPARGC1B, PRKCQ, ADM, PIK3R3, GNG4, IHH, MB
  GO:0042060\~wound healing                                  1.36×10^3^    PRKCQ, FOXA2, CD40LG, SAA1, SERPINE1, GNA12, HBEGF, SCARB1, LMAN1, PLAU, RAB27A
  GO:0009611\~response to wounding                           1.37×10^3^    YWHAZ, FOXA2, GNA12, LYZ, LMAN1, CCL5, IL10, C8B, PRKCQ, ADM, TFRC, CD40LG, SAA1, SERPINE1, HBEGF, NFE2L1, SCARB1, CTSB, PLAU, RAB27A
  GO:0007155\~cell adhesion                                  1.42×10^3^    PVR, CLDN8, DCHS2, TYRO3, CADM1, COL13A1, CLDN3, COL22A1, CTNND2, COL2A1, ITGA4, CCL5, CDH5, CHAD, ISLR, CD40LG, COL6A2, COL6A1, LAMC2, SCARB1, CNTN3, LAMC1, TGFB1I1, PARVA
  GO:0022610\~biological adhesion                            1.45×10^3^    PVR, CLDN8, DCHS2, TYRO3, CADM1, COL13A1, CLDN3, COL22A1, CTNND2, COL2A1, ITGA4, CCL5, CDH5, CHAD, ISLR, CD40LG, COL6A2, COL6A1, LAMC2, SCARB1, CNTN3, LAMC1, TGFB1I1, PARVA
  GO:0002684\~positive regulation of immune system process   2.14×10^3^    PVR, C8B, IRAK1, PRKCQ, NCK2, CADM1, SLA2, VEGFA, CD247, TNFRSF13C, AP3D1, SPN
  GO:0007599\~hemostasis                                     2.16×10^3^    FOXA2, CD40LG, SAA1, SERPINE1, GNA12, LMAN1, PLAU, RAB27A
  GO:0016337\~cell-cell adhesion                             2.28×10^3^    PVR, CLDN8, DCHS2, CADM1, COL13A1, CD40LG, CLDN3, CTNND2, COL6A2, COL2A1, ITGA4, CDH5, CHAD
  GO:0008285\~negative regulation of cell proliferation      2.91×10^3^    RBBP4, BAP1, GJA1, SKI, SESN1, GLI3, IL10, CDH5, MSX2, NCK2, ADM, MYO16, HGS, TGFB1I1, SPN
  GO:0048545\~response to steroid hormone stimulus           4.86×10^3^    CALCR, ADM, SOCS3, ACADS, STRN3, LEPR, CCL5, IL10, PPARGC1B, IHH
  GO:0016477\~cell migration                                 6.55×10^3^    PVR, NCK2, DRD1, ULK1, SAA1, HBEGF, SCARB1, LAMC1, ITGA4, CCL5, IL10, PLAU
  GO:0016055\~Wnt receptor signaling pathway                 6.81×10^3^    FZD9, WNT7B, FZD10, FRAT1, FRAT2, TGFB1I1, FRZB, FZD7
  GO:0001666\~response to hypoxia                            7.08×10^3^    PRKCQ, TFRC, ADM, SOCS3, CLDN3, VEGFA, PLAU, MB
  GO:0042981\~regulation of apoptosis                        7.81×10^3^    IRAK1, YWHAZ, CADM1, SOCS3, EIF5A, TRIO, COL2A1, FOXO3, GLI3, IL10, MSX2, CD40LG, BAG3, VEGFA, DIABLO, PSENEN, DNAJC5, CTSB, DDAH2, ARHGDIA, TRAF4, SPN, RAB27A, IHH
  GO:0044271\~nitrogen compound biosynthetic process         8.29×10^3^    FECH, ATP4A, ADCY5, AK5, CMPK2, ADM, CPOX, NFE2L1, THNSL1, FPGS, DDAH2, IMPDH1, NT5E
  GO:0010648\~negative regulation of cell communication      8.62×10^3^    DRD1, SOCS3, STRN3, SLA2, HGS, SKI, TGFB1I1, FRZB, CHRD, IHH, RGS13
  GO:0043067\~regulation of programmed cell death            8.74×10^3^    IRAK1, YWHAZ, CADM1, SOCS3, EIF5A, TRIO, COL2A1, FOXO3, GLI3, IL10, MSX2, CD40LG, BAG3, VEGFA, DIABLO, PSENEN, DNAJC5, CTSB, DDAH2, ARHGDIA, TRAF4, SPN, RAB27A, IHH
  GO:0010941\~regulation of cell death                       9.12×10^3^    IRAK1, YWHAZ, CADM1, SOCS3, EIF5A, TRIO, COL2A1, FOXO3, GLI3, IL10, MSX2, CD40LG, BAG3, VEGFA, DIABLO, PSENEN, DNAJC5, CTSB, DDAH2, ARHGDIA, TRAF4, SPN, RAB27A, IHH
  GO:0001503\~ossification                                   1.24×10^2^    FGF18, TNFSF11, COL13A1, DMP1, COL2A1, CHRD, IHH
  GO:0048870\~cell motility                                  1.38×10^2^    PVR, NCK2, DRD1, ULK1, SAA1, HBEGF, SCARB1, LAMC1, ITGA4, CCL5, IL10, PLAU
  GO:0051674\~localization of cell                           1.38×10^2^    PVR, NCK2, DRD1, ULK1, SAA1, HBEGF, SCARB1, LAMC1, ITGA4, CCL5, IL10, PLAU
  GO:0043066\~negative regulation of apoptosis               1.55×10^2^    MSX2, IRAK1, YWHAZ, CD40LG, SOCS3, BAG3, VEGFA, DNAJC5, COL2A1, DDAH2, IL10, ARHGDIA, IHH
  GO:0060348\~bone development                               1.68×10^2^    FGF18, TNFSF11, COL13A1, DMP1, COL2A1, CHRD, IHH
                                                                           
  **B, KEGG pathway**                                                      
                                                                           
  **Term**                                                   **P-value**   **Genes**
                                                                           
  hsa04512:ECM-receptor interaction                          4.33×10^3^    COL4A2, COL6A2, COL6A1, LAMC2, COL2A1, LAMC1, ITGA4, CHAD
  hsa04510:Focal adhesion                                    1.00×10^2^    COL4A2, VEGFA, COL6A2, COL6A1, LAMC2, COL2A1, LAMC1, ITGA4, PIK3R3, CRK, CHAD, PARVA
  hsa00230:Purine metabolism                                 1.25×10^2^    PDE7B, PDE2A, ADCY5, PDE4A, ENTPD6, AK5, ENTPD4, POLR2D, NT5E, IMPDH1
  hsa04150:mTOR signaling pathway                            3.80×10^2^    ULK1, VEGFA, ULK3, PRKAA2, PIK3R3
  hsa04514:Cell adhesion molecules (CAMs)                    4.30×10^2^    PVR, CLDN8, CADM1, CD40LG, CLDN3, ITGA4, CDH5, SPN
  hsa04310:Wnt signaling pathway                             4.77×10^2^    FZD9, WNT7B, FZD10, PPP2R5B, FRAT1, FRAT2, PPP3CA, FZD7
  hsa04920:Adipocytokine signaling pathway                   4.82×10^2^    PRKCQ, SOCS3, RXRB, LEPR, PRKAA2
  hsa04660:T cell receptor signaling pathway                 4.90×10^2^    PRKCQ, NCK2, CD40LG, CD247, PPP3CA, PIK3R3, IL10

GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.

###### 

Function enrichment for genes in the long non-coding RNA-microRNA-mRNA competing endogenous RNA network.

  A, Biological process                                                        
  -------------------------------------------------------------- ------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GO:0002684\~positive regulation of immune system process       1.01×10^3^    PVR, C8B, PRKCQ, NCK2, CADM1, SLA2, VEGFA, CD247, SPN
  GO:0010033\~response to organic substance                      3.44×10^3^    IL1R1, SOCS3, STRN3, LEPR, ADCY5, PPARGC1B, MSX2, ERP44, PRKCQ, ADM, TFRC, COL6A2, PIK3R3, GNG4, IHH
  GO:0007166\~cell surface receptor linked signal transduction   3.57×10^3^    IL1R1, LEPR, ADCY5, GNA12, CD247, FST, CCL28, LGR4, ADCYAP1, MSX2, NMUR1, OXER1, FRAT1, FRAT2, GNG4, PIK3R3, SPN,PTGER2, SLA2, ITGA4, FZD7, RGS13, EPS15, NCK2, WNT7B, ADM, P2RY14, VEGFA
  GO:0009725\~response to hormone stimulus                       4.30×10^3^    PRKCQ, ADM, SOCS3, STRN3, ADCY5, LEPR, PIK3R3, GNG4, PPARGC1B, IHH
  GO:0042127\~regulation of cell proliferation                   7.37×10^3^    PTGER2, RBBP4, BAP1, CDC25B, MSX2, PRKCQ, NCK2, ATF3, ADM, VEGFA, SERPINE1, MYO16, LAMC1, SPN, IHH
  GO:0009719\~response to endogenous stimulus                    8.05×10^3^    PRKCQ, ADM, SOCS3, STRN3, ADCY5, LEPR, PIK3R3, GNG4, PPARGC1B, IHH
  GO:0043062\~extracellular structure organization               1.31×10^2^    WNT7B, CADM1, ANK3, DMP1, COL6A2, LAMC1
  GO:0007568\~aging                                              1.48×10^2^    PRKCQ, TFRC, ADM, SOCS3, SERPINE1
  GO:0045137\~development of primary sexual characteristics      2.37×10^2^    LEPR, FST, VEGFA, FOXO3, LGR4
  GO:0048545\~response to steroid hormone stimulus               2.48×10^2^    ADM, SOCS3, STRN3, LEPR, PPARGC1B, IHH
  GO:0008284\~positive regulation of cell proliferation          2.60×10^2^    PRKCQ, NCK2, ATF3, ADM, VEGFA, LAMC1, SPN, CDC25B, IHH
  GO:0001666\~response to hypoxia                                2.81×10^2^    PRKCQ, TFRC, ADM, SOCS3, VEGFA
  GO:0008202\~steroid metabolic process                          2.99×10^2^    CYP3A4, SOAT1, SULT2A1, ADM, LEPR, PRKAA2
  GO:0016337\~cell-cell adhesion                                 3.15×10^2^    PVR, CADM1, COL13A1, CTNND2, COL6A2, ITGA4, CHAD
  GO:0070482\~response to oxygen levels                          3.31×10^2^    PRKCQ, TFRC, ADM, SOCS3, VEGFA
  GO:0050778\~positive regulation of immune response             3.61×10^2^    PVR, C8B, CADM1, SLA2, CD247
  GO:0007548\~sex differentiation                                4.09×10^2^    LEPR, FST, VEGFA, FOXO3, LGR4
                                                                               
  **B, KEGG pathway**                                                          
                                                                               
  **Term**                                                       **P-value**   **Genes**
                                                                               
  hsa00230:Purine metabolism                                     3.14×10^3^    PDE7B, ADCY5, PDE4A, ENTPD6, AK5, ENTPD4, POLR2D, NT5E
  hsa04510:Focal adhesion                                        3.77×10^3^    VEGFA, COL6A2, COL6A1, LAMC2, LAMC1, ITGA4, PIK3R3, CRK, CHAD
  hsa04512:ECM-receptor interaction                              4.15×10^3^    COL6A2, COL6A1, LAMC2, LAMC1, ITGA4, CHAD
  hsa04920:Adipocytokine signaling pathway                       1.02×10^2^    PRKCQ, SOCS3, RXRB, LEPR, PRKAA2
  hsa04150:mTOR signaling pathway                                2.82×10^2^    VEGFA, ULK3, PRKAA2, PIK3R3
  hsa04062:Chemokine signaling pathway                           2.90×10^2^    ADCY5, FOXO3, PIK3R3, GNG4, CRK, CCL28
  hsa04310:Wnt signaling pathway                                 3.13×10^2^    WNT7B, PPP2R5B, FRAT1, FRAT2, FZD7
  hsa04660:T cell receptor signaling pathway                     3.16×10^2^    PRKCQ, NCK2, CD247, PIK3R3
  hsa03320:PPAR signaling pathway                                3.22×10^2^    RXRB, SCD, SLC27A2
  hsa04514:Cell adhesion molecules (CAMs)                        3.23×10^2^    PVR, CADM1, ITGA4, SPN
  hsa04810:Regulation of actin cytoskeleton                      3.29×10^2^    GNA12, RDX, ITGA4, PIK3R3, CRK

GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.
